Columbia, MD – (December 8, 2014) – ACell, Inc. today announced that a peer-reviewed study, “Esophageal Reinforcement with an Extracellular Scaffold During Total Gastrectomy for Gastric Cancer,” was published in the October, 2014 issue of Annals of Surgical Oncology, featuring its MatriStem Surgical Matrix PSM device.
The retrospective study compared the rate of anastomotic leaks after total gastrectomy in two patient groups – one group that had esophageal reinforcement using MatriStem Surgical Matrix PSM and a second group as a control. 2.7% of patients in the MatriStem group had a postoperative leak, compared to 12% in the control group – a reduction of more than 75%.
“Post-operative leaks are a potentially devastating complication of esophageal reinforcement, with morbidity rates approaching 50%” said Thomas Gilbert, Ph.D., Vice President of Research and Development at ACell. “Various approaches have been developed and tried with the hopes of reducing the occurrence of post-operative leaks, but none have been widely accepted by the clinical community.”
Post-operative leaks can also increase the incidence of strictures (narrowing of the esophagus) and have a negative impact on the patient’s nutritional status.
Gastrectomy is a surgical procedure that removes a patient’s stomach; typically the surgeon then connects the esophagus directly to the small bowel with a procedure called anastomosis. A full or partial gastrectomy is usually the only curative measure for patients with primary stomach cancer, which affects more than 20,000 Americans each year.
“The research presented is very promising and could represent a significant step forward in treating stomach cancer patients who have undergone total gastrectomy,” said Gilbert. “We have initiated a prospective study with the same research team to further examine the potential for MatriStem technology to improve outcomes after esophageal anastomosis, which we believe will validate these initial promising results and lead to broader adoption of the technique.”
About ACell, Inc.
ACell, Inc. is a leading company in the field of regenerative medicine, focused on the development, manufacturing and commercialization of tissue repair products. Its medical devices are cleared for a variety of indications and are marketed under the brand name “MatriStem.” A privately held company, ACell produces MatriStem at its full scale manufacturing facility in Lafayette, IN, and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.
MatriStem products are porcine-derived extracellular matrix (ECM) scaffolds that contain the epithelial basement membrane from porcine urinary bladder tissue, or urinary bladder matrix (UBM). UBM is a layer of tissue that facilitates a constructive tissue remodeling response by the patient’s body. It provides MatriStem products with several distinguishable characteristics, including the ability to be resorbed by the patient as it is replaced by site appropriate tissue following implantation; the ability to be used “off-the-shelf” and stored at room temperature, with up to a two year shelf life; and superior ease-of-use characteristics. MatriStem products are indicated for use in a wide range of tissue repair applications and come in a range of sizes and thicknesses. They have been cleared for use in general surgery, gynecological surgery and a wide range of wounds, including diabetic foot ulcers (DFU), venous leg ulcers (VLU), pressure, surgical, and tunneled wounds. Refer to the IFU supplied with each device for indications, contraindications and precautions. All MatriStem devices are made in the USA.Return to News